−7,−6,−5 mol/L) decreased contractility in the hypertrophied, but not normal RV, in a dose-dependent manner (P<0.01). 
T he increased levels of endothelin (ET)-1 in the pulmonary arteries and serum of patients with pulmonary arterial hypertension (PAH) contribute to the vasoconstriction and proliferative vascular remodeling that characterize PAH. 1, 2 Several ET receptor antagonists (ERAs) are now either approved or under clinical trials for PAH. The initial enthusiasm after the recognition of the role of ET-1 in PAH and the beneficial pulmonary vascular effects in animal models was limited by the realization that these drugs can offer only a small, but potentially important, benefit in PAH patients. 3 PAH remains an untreatable disease, leading to progressive worsening of right ventricular (RV) function, heart failure, and death. 4, 5 In This Issue, see p 223
Editorial, see p 227
Although the most important determinant of morbidity and mortality in PAH is RV function, 6 ,7 the effects of most PAH therapies on RV function are unknown. In atrial or left ventricular (LV) myocardium from animals [8] [9] [10] [11] [12] [13] or humans, [14] [15] [16] [17] [18] ET-1 has direct positive inotropic effects mediated by the ET type A receptor (ET R -A) and ERAs decrease contractility. In neonatal mouse RV cardiomycytes, ET-1 increased contractility via an increase in intracellular Ca 2+ transients through activation of the ET R -A receptor and an increase in Ca 2+ influx via the Na + -Ca 2+ exchanger during the action potential. 19 In clinical trials of LV failure, where circulating levels of ET-1 are also increased like in PAH, ERAs worsened outcomes (in part as a result of early worsening of heart failure and fluid retention), prompting a premature ending of trials and the development of these drugs for congestive heart failure. 20, 21 It is thus surprising that the possibility of direct effects January 18, 2013
on RV function in ERA-treated PAH patients is not typically considered. Several trials showed a decrease in pulmonary artery pressure, but lack of the expected improvement in cardiac index, with either ET R -A-selective or nonselective ERAs. [22] [23] [24] Furthermore, several ERAs, including ET R -A antagonists, are associated with increased incidence of edema. Although this seems to be a class effect, additional postmarketing reports of edema to the Food and Drug Administration (at times requiring hospitalization for decompensated heart failure) within a few weeks from ambrisentan initiation, led to a black box warning for significant edema in ERA labels. In clinical practice, edema is assumed to be attributable to renal effects of these drugs on sodium reabsorption and may not lead to discontinuation of ERA therapy. However, it is known that such effects are mediated by the ET type B receptor, not the ET R -A. 25 We speculated that such cases could represent potential early reduction of RV contractility. Indeed, there is recent evidence to suggest that a group of PAH patients who were treated with therapies including ERAs, despite an early decrease in pulmonary vascular resistance, progress with worsening of RV function (measured by MRI) and poor outcomes 5 ; supporting the concept that a therapy like ERAs may adversely worsen RV function in parallel to beneficial effects on the pulmonary arteries.
Nonetheless, negative acute inotropy is not necessarily a weakness of PAH drugs in the long term. For example, β-receptor antagonists have negative inotropy on the LV myocardium but unquestionable benefits in the long-term treatment of LV dysfunction. However, trials with β-receptor antagonists were never terminated as a result of early worsening of heart failure, as seen with ERAs and heart failure. 21 We hypothesized that the ET-1 axis is upregulated in the hypertrophied RV, potentially as part of a compensatory response, promoting hypertrophy and increased contractility, as the RV afterload increases in PAH. We also hypothesized that ERAs will have negative inotropic effects directly on the hypertrophied RV myocardium. Protein and mRNA expression of ET-1 and ET receptors were measured in RV tissues (hypertrophied versus nonhypertrophied) from 50 patients and from rats, and also the direct effects of ET-1 and ERAs on RV myocardium were studied in a modified RV-Langendorff model.
Methods
All experiments on human tissues and rats were performed with permission from the University of Alberta committees on human ethics and animal policy and welfare, respectively. Please see the expanded Methods section in the Online Data Supplement.
Human Specimens
We prospectively collected and studied RV specimens from 50 patients (hypertrophied RV=34, nonhypertrophied RV=16; Online Table I ). The RV tissue came from surgery or transplant materials. The quantification of RV hypertrophy (RVH) was made by echocardiography in the perioperative period, measuring RV free-wall thickness in at least 2 standard views 26 by blinded cardiologists.
Immunohistochemistry and Confocal Microscopy
Confocal microscopy with multiple-staining technique and timecoursed image acquisition was used to quantify the expression of ET-1 and ET receptors in RV myocardium, as previously described.
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Laser-Captured Microdissection and Quantitative Reverse Transcriptase Polymerase Chain Reaction
Laser-captured microdissection and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was performed on human and rat RV tissues for ET-1 and ET R -A, using an Arcturus laser-captured microdissection system and commercially available primers in an Applied Biosystems qRT-PCR machine (ABI PRISM 7700), as previously described.
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Animal Model of RVH
We studied hypertrophied rat RVs (n=23) versus normal RVs (n=28). Rats developed severe PAH (confirmed with echocardiography and catheterization) and RVH, 3 weeks after a single injection of monocrotaline. We quantified RVH (RV divided by LV+septum weight ratio) and processed the RV tissue for histology, laser-captured microdissection, and qRT-PCR.
28,31-36
Isolated RV-Langendorff Perfusion
A modified Langendorff perfusion model was adapted to measure developed pressure in the RV, and was performed as previously described. 29, 30 The ex vivo perfusion of the heart is critical to separate the concomitant effects ERAs would have on the pulmonary vasculature during in vivo studies, where a decrease in pulmonary vascular resistance may mask direct effects on RV myocardium.
ET Immunoassay
A commercially available ELISA kit (Cayman Chemicals, Ann Arbor, MI) with a double-antibody sandwich technique was used.
Data Analysis
Data were expressed as mean+SEM, and differences were evaluated using the Student t test for unpaired data or 1-way ANOVA followed by post hoc Bonferroni correction. Linear regression was performed on human ET R -A and ET-1 expression versus a standard RVH index (RV free-wall thickness divided by body surface area). Significance was defined as P<0.05 (SPSS 17.0, SPSS Inc, Chicago, IL).
Results
There was a significant increase in the levels of both ET-1 (+240%) and ET R -A protein (+125%) in the RV myocardium of patients with RVH, compared with those with nonhypertrophied RVs, measured by immunohistochemistry and confirmed with immunoblots ( Figure 1 ). Colocalization with the cardiomyocyte marker myosin heavy chain showed that this upregulation occurred in the myocardium. The ET receptor type B was only observed in the coronary vasculature (stained with smooth muscle actin) of both hypertrophied and nonhypertrophied RV, and not in the myocardium. Overall, the levels of ET receptor type B protein did not differ between the nonhypertrophied and hypertrophied RV myocardium (Online Figure I) .
To determine whether there is a relation between the degree of RVH and the upregulation of the ET-1 axis in RV myocardium we plotted the levels of ET-1 or ET R -A against each patient's RVH index. There was a strong positive correlation between the degree of RVH and the amount of both ET-1 and ET R -A. The more hypertrophied the RV, the stronger the ET axis upregulation was ( Figure 2A ). To determine whether ET-1 and ET R -A mRNA were also increased in the RV myocardium, we used qRT-PCR and lasercaptured microdissection. This technique allows for cuts of either muscle or vessel, determined visually and confirmed by the relative amount of myosin heavy chain and smooth muscle actin mRNA that amplifies within the cut. There was increased expression of both ET-1 and ET R -A mRNA in the hypertrophied compared with the nonhypertrophied RV myocardium ( Figure 2B ). The mRNA increase in the hypertrophied versus nonhypertrophied tissues was similar to the increase in the protein level, that is, +230% for the ET-1 and +100% for the ET R -A. This upregulation was specific for the myocardium cuts (high ratio of myosin heavy chain to smooth muscle actin) because the mRNA levels did not differ in the vessel cuts (low ratio).
The human tissue immunohistochemistry and laser-captured microdissection data were recapitulated in a standard rat model of RVH secondary to monocrotaline-induced PAH. Hypertrophied rat RVs (high "RV/LV+septum" weight ratio and histological evidence of hypertrophied cardiomyocytes) had increased myocardial expression of both ET-1 and ET R -A protein and mRNA, compared with normal RVs from vehicletreated rats (Figure 3, Online Figures II and III) . Studies on the LV myocardium from the same animals showed that the ET R -A protein levels did not differ between the LVs of the same animals (Online Figure IV) . This suggested that the upregulation of the ET R -A was intrinsic to the hypertrophic process in the RV and not due to a circulating factor.
We then used a model in which RV contractility could be studied directly in isolated perfused rat hearts while preload and afterload remain constant, as we have previously described. 29, 30 Both hypertrophied and normal RV hearts showed an increase in developed pressure from baseline when treated with the β-agonist isoproterenol or ET-1 ( Figure 4A and 4B) . Two different ERAs (the ET R -A antagonist BQ-123 and bosentan, a nonselective ERA used in PAH) 37, 38 caused a significant and reversible decrease in RV developed pressure in hypertrophied, but not normal RVs ( Figure 4A and 4B, Online Figure V) . The negative RV inotropic effect of bosentan was dose-dependent. The exogenous positive inotropic effect of ET-1 was effectively reversed when bosentan was added to the perfusate (Online Figure VI) . Bosentan decreased both positive and negative delta pressure/delta time (dp/dt), suggesting negative effects in both contractility and lucitropy (Online Figure VII) . Heart rates of the hypertrophied RVs remained similar during perfusion with ERAs (194±16.8 versus 182±19.3 at baseline and during bosentan infusion, respectively). There were also no significant changes in coronary blood flow during bosentan infusion (Online Figure VIII) . The ET-1 concentration in the coronary sinus effluent in hearts with hypertrophied RV ex vivo was higher compared with the normal RV at baseline and increased further by isoproterenol ( Figure 4C ). Although the coronary sinus effluent reflects blood returning from both ventricles, the increase in ET-1 is likely a result of its upregulation in the hypertrophied RV. β-agonist spillover of ET-1 has previously been described, suggesting that the upregulated ET-1 axis in the hypertrophied RV could have important autocrine/paracrine effects, 39 particularly in response to sympathetic activation. The systemic Table I and Method sections. B, Laser-captured microdissection (LCM) and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) were applied on human RV tissue. LCM was used to isolate myocardium vs coronary arteries in normal and hypertrophied human RV tissue, which was then studied with qRT-PCR. A myocardium sample was characterized by a high myosin heavy chain (MHC) to smooth muscle actin (SMA) ratio (black bars), whereas a coronary artery sample was characterized by a low MHC to SMA ratio. Endothelin-1 (white bars) and ET R -A (gray bars) mRNA is markedly increased in RV hypertrophy (RVH) compared with normal RV myocardium, whereas it is similarly expressed in the coronary vessels, in agreement with the immunohistochemistry data in Figure 1 . venous blood from rats with PAH and RVH had increased concentrations of ET-1, compared with the control rats; and these levels were ≈50 times higher than the levels of ET-1 in the coronary sinus effluent ( Figure 4D) . Thus, the increased production of ET-1 by the RVH hearts may have autocrine and paracrine effects ( Figure 4E ), though it may not contribute significantly to the circulating ET-1 levels.
Discussion
We show that the ET axis is upregulated in the human hypertrophied RV myocardium (both at the protein and mRNA levels), and that there is a strong positive correlation between the expression of ET R -A and ET-1 and the degree of hypertrophy. The same upregulation also occurs in hypertrophied rat RVs, but not in the LVs of the same animals (which are not hypertrophied). We also show that ERAs have direct effects only on the hypertrophied rat RV, decreasing contractility and lucitropy. The induction of ET-1 and ET R -A in the hypertrophied RV in PAH, might serve as an early adaptive mechanism that would promote hypertrophy and maintain contractility as the RV afterload increases. The increased sympathetic drive from the upregulation of the neurohormonal axis in PAH could be responsible for the increased production of ET-1 by the RVH myocardium. β-agonists cause a calcineurin-mediated increase in the ET-1 promoter activity in cardiomyoctyes. 40 The paracrine/autocrine effects of increased RVH production of ET-1 can also help maintain cardiomyocyte survival in the environment of sustained increase in β-adrenergic stimulation in PAH. ET-1 is known to abate the proapoptotic effects of β-agonists on cardiomyocytes. 41 The fact that the myocardial ET-1 axis is upregulated in exercise-induced LV hypertrophy 42 suggests that it plays a role in the adaptive and physiological hypertrophy process. The RV ET-1 can have paracrine or autocrine inotropic effects, 9 and the presence of ET-converting enzyme in myocardial cells suggests that the cardiomyocyte ET-1 is biologically active. 43 It is unlikely that the upregulation of the ET-1 axis in RVH is attributable to a circulating factor, like an inflammation mediator, for example. The fact that in the monocrotaline model (characterized by a strong inflammatory environment) this upregulation does not take place in the LV (which is exposed to the same circulating factors) suggests that it is intrinsic to the RVH process (Online Figure IV) . Nevertheless, our study cannot rule out the intriguing possibility that the ET-1 axis upregulation occurs in parallel to (rather than following) the increase in afterload, independently driving the hypertrophy process, at least in part. In this ex vivo modified Langendorff preparation, a balloon with a pressure transducer is placed in the RV and spontaneous contractility is measured as previously described. 29, 30 The balloon volume (preload) and the afterload (ligated pulmonary artery) are fixed. Perfusion with an ERA causes a decrease in developed pressure that can be washed off with a return to baseline. B, Mean data showing that the RV developed pressure is decreased in response to an endothelin type A receptor (ET R -A) antagonist (BQ-123) and a nonselective ERA (bosentan) in a dose-dependent manner, in the hypertrophied (n=11) but not the normal RV (n=9). Both normal and hypertrophied RV responded similarly to isoproterenol and endothelin-1 (ET-1; *P<0.01 dose-response in hypertrophied vs nonhypertrophied RV). C, Endothelin-1 secretion from the myocardium (coronary sinus effluent during modified Langendorff perfusion) is increased in RV hypertrophy and is further augmented by β-adrenergic stimulation with isoproterenol 10 -7 mol/L. D, Circulating concentration of ET-1 in the venous blood of the same rats with (n=11) and without RV hypertrophy (RVH; n=9; *P<0.01 vs baseline, #P<0.01 vs normal RV). E, A schematic of proposed autocrine/paracrine effects of ET-1 on cardiomyocytes to support contractility in RV hypertrophy. β-Ad R indicates β-adrenergic receptor.
Although advanced PAH is essentially a heart failure syndrome, despite the heavy clinical use of ERAs, the possibility that these drugs have direct effects on RV function is currently not considered. 4 Both nonselective (bosentan) or ET R -A selective ERAs (ambrisentan, sitaxsentan) are often associated with significant edema, early after the initiation of therapy. These effects could be attributable to a negative inotropic effect on the RV. Previous data 44 as well as the current work showing that the ET-1 axis is upregulated in RVH, suggest that ERAs could blunt this potentially beneficial response to hypertrophy. In published hemodynamic clinical studies, an ERA-induced decrease in pulmonary artery pressure is not always associated with evidence of improved RV function as one would expect.
Ambrisentan, 23 at the approved dose of 10 mg, and sitaxsentan 22 decreased the pulmonary artery pressure by 13 and 11 mm Hg, respectively (P<0.05 for both), but the right atrial pressure and cardiac index did not improve. In fact, in the sitaxsentan trial, where individual patient responses were shown, 37% of patients had an actual decrease in the cardiac index. 22 Edema developed in 45% of the sitaxsentan-treated patients in that trial and in 25% of the patients in the ambrisentan trial. 22, 23 In patients with PAH resulting from Eisenmenger syndrome, bosentan decreased the pulmonary artery pressure, yet edema developed in 19% of the cohort. 24 In another study, a direct, blinded comparison between sildenafil and bosentan showed that although the 2 drugs improved the pulmonary artery pressure similarly, RV ejection fraction (measured by MRI) improved in the sildenafil but not the bosentan group. 45 Recently, van de Veerdonk et al 5 studied a cohort of PAH patients on therapy (75% using ERAs) for >12 months. Despite decreases in pulmonary vascular resistance there was a progression of RV deterioration from baseline in 25% of treated patients, which was associated with poor outcomes. Taken together, these data suggest that ERAs may decrease RV function in some patients with PAH, blunting any beneficial effects that these drugs may have by the decrease in PA pressure.
Several studies on human cardiomyocytes, [14] [15] [16] [17] [18] have shown that ET-1 increases inotropy, and in that sense its upregulation in the diseased LV might be beneficial. For example, in mouse hypertrophied LV there is significant upregulation of the ET R -A and ET-1 compared with normal LV and bosentan inhibits contractility in response to increasing end-diastolic pressures (Frank Starling mechanism) by 52% in the hypertrophied but not the normal LV. 10 Inhibition of a potentially adaptive upregulation of the ET axis could explain the increased morbidity shown in patients with LV failure treated with ERAs. 20, 21 Potential effects on the RV need to be studied in both animal, human tissues, and clinical trials in all therapies used to treat PAH patients. For example, although phosphodiesterase type 5 is not significantly expressed in the normal RV, its expression is induced in RVH and phosphodiesterase type 5 inhibitors (the other class of approved oral drugs in PAH) can have positive inotropic effects in the hypertrophied RV myocardium. 29, 46 We propose that the beneficial effects of ERAs in decreasing the RV afterload, by reversing pulmonary artery vasoconstriction and remodeling, may be limited by a potential negative inotropic effect on the RV, at least in some patients. This negative effect on contractility may be small and might not take place in all patients treated. For example, we only studied patients and rats with hypertrophied and compensated RVs; not patients and rats with dilated and decompensated ventricles, where ET receptors may be downregulated. In such patients ERAs may not have negative inotropy. 18 Such patients likely have symptoms of World Health Organization functional class III and IV. Clinically, once patients have transitioned to decompensated RV failure, the prognosis is exceedingly poor and the opportunity to positively impact survival is low, which is why we have focused this study on patients and animals with compensated RVH. Also, there is now a tendency to expand the use of ERAs in patients with World Health Organization functional class II. 47 In such patients with compensated RVH, ERAs may adversely affect the RV function acutely. Nevertheless, long-term effects cannot be extrapolated from our data.
The dose-dependent effects of bosentan on RV contractility/ lucitropy at doses within the range of bosentan serum levels in treated patients 37, 38 suggest that they are clinically relevant. Because BQ-123 had the same effects, this is likely an ERA class effect. The presence of early edema in patients treated with ERAs might be an indication to discontinue the ERA therapy, rather than just adding diuretics, as is currently the practice. Future trials of ERAs in PAH should study their effects in prospectively identified subgroups, based on RV size and function, allowing for improved outcomes in the subgroups that do not show evidence of negative RV inotropy and avoiding deterioration in those patients in whom the ET-1 axis was contributing to a beneficial compensation against the increasing RV afterload. 
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